France · 
What does Sofinnova Partners invest in?
Sofinnova Partners invests most often at Series A and Series B (59% of the rounds on record), in sectors such as Bio, Digital-health and Life Science.
Sofinnova Partners highlights
- 01
31 cheques in the last 12 months
- 02
Mostly Series A and Series B: 59% of its rounds
- 03
Sole investor in 23 rounds, median $5.4M
- 04
17 exits from the portfolio
What they do
Sofinnova Partners invests in life sciences innovation worldwide, from biopharma and medtech to digital medicine and industrial biotech.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $1.0M – $60M as they say
- Stages
- Pre-seedSeedSeries ASeries BGrowthPre-IPO
- Sectors
- BioDigital-healthLife Science
- Based in
- Paris, France
- Cold pitches
- Accepted
The record
Every round we can evidence, newest first232 appearances
- 2026
24 rounds
- Oct
- Oct
- Sept
- Sept
- Sept
- Sept
- Aug
- Jun
- Jun
- Jun
- Jun
- Jun
- May
- May
- May
- May
- Apr
- Mar
- Feb
- Jan
- Jan
- Jan
- Jan
- Jan
- 2025
26 rounds
- Dec
- Dec
- Nov
- Nov
- Nov
- Nov
- Nov
- Oct
- Oct
- Oct
- Oct
- Oct
- Sept
- Sept
- Jul
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration6 named
APAntoine PapiernikManaging Partner and ChairmaniForm ADV
CBChristophe BlancheDirector of General PartneriFiling they signed
GSGraziano SeghezziManaging Partner of AIFMiFiling they signed
HRHenrijette RichterManaging Partner of AIFMiFiling they signed
MKMats Kristian EklundChief Operating Officer and Directeur GeneraliForm ADV
QLQuentin LevequeDirector of General PartneriFiling they signed
We also hold 88 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$1.9Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Sofinnova Partners SAS
- SEC number
- CRD 164104
Exits from the portfolio
Companies it backed that were later bought or listed17 in all
GlycoVaxynBought by GSK Venture Fund$190MFeb 2015
mydecoBought by MONOQIUndisclosedJan 2015
Omthera PharmaceuticalsBought by AstraZeneca$443MMay 2013
BioAmberListed$80MMay 2013
blueKiwiBought by AtosUndisclosedApr 2012
Laszlo SystemsBought by Critical Path Inc.UndisclosedFeb 2012
PregLemBought by Richter GroupUndisclosedOct 2010
UPEKBought by AuthenTecUndisclosedSept 2010
StreamezzoBought by AmdocsUndisclosedApr 2010
Sensitive ObjectBought by Tyco Electronics$62MJan 2010
Fovea PharmaceuticalsBought by Sanofi AventisUndisclosedOct 2009
Purple LabsBought by Myriad$101MFeb 2009
BiolipoxBought by OrexoUndisclosedNov 2007
AblynxListedUndisclosedNov 2007
EnvoyWorldWideBought by VaroliiUndisclosedDec 2005
An exit counts when it came after the firm's first round in the company. From historical deal records.